drugset / Trial / NCT01192698
Intravenous Interferon During Liver Transplant
Completed
15 enrolled
Wake Forest University Health Sciences
American College of Gastroenterology · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation. The hypothesis is that patients who receive ribavirin immediately before transplant and intravenous interferon alfa 2b during the anhepatic phase(while the liver is removed)will have sustained virologic response post liver transplant.
Timeline
- Start
- 2009-10
- Primary completion
- 2013-02
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interferon alfa-2b | Protein / enzyme biologic | 5e+06 iu | Intravenous |